Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective modulation of thyroid hormone receptor action.

J D Baxter1, W H Dillmann, B L West

  • 1Metabolic Research Unit, Department of Medicine, University of California, San Francisco, CA 94143, USA. jbaxter918@aol.com

The Journal of Steroid Biochemistry and Molecular Biology
|June 1, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.

HIV medicine·2020
Same author

Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas.

Oncogene·2017
Same author

Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

HIV medicine·2015
Same author

Patents and literature.

Applied biochemistry and biotechnology·2013
Same author

Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange.

Molecular endocrinology (Baltimore, Md.)·2010
Same author

Crystallization and preliminary X-ray diffraction studies of isoform alpha1 of the human thyroid hormone receptor ligand-binding domain.

Acta crystallographica. Section D, Biological crystallography·2004

Selective thyroid hormone receptor (TR) modulators offer therapeutic potential. Researchers developed GC-1, a TRbeta-selective compound, demonstrating cholesterol-lowering benefits without cardiac side effects in preclinical studies.

Area of Science:

  • Endocrinology and Molecular Pharmacology
  • Structural Biology and Drug Discovery

Background:

  • Thyroid hormones (THs) exert beneficial effects like weight loss and cholesterol reduction, but also deleterious cardiac and bone effects.
  • Selective modulation of thyroid hormone receptor (TR) isoforms (TRalpha and TRbeta) is a therapeutic goal to separate beneficial from adverse actions.
  • Previous attempts at selective TR modulation lacked detailed mechanistic understanding.

Purpose of the Study:

  • To investigate the structural basis for TRalpha and TRbeta selectivity.
  • To develop and characterize a TRbeta-selective compound (GC-1) with potential therapeutic applications.
  • To evaluate the in vivo efficacy and safety profile of GC-1.

Main Methods:

  • Determined X-ray crystal structures of TRalpha and TRbeta ligand-binding domains (LBDs) complexed with Triac.

Related Experiment Videos

  • Synthesized and tested the compound GC-1, featuring an oxoacetate moiety, for TRbeta-selective binding and action in vitro.
  • Assessed GC-1's effects on cholesterol, triglycerides, heart rate, cardiac parameters, and TSH levels in vivo (tadpoles and mice).

    • Main Results:

    • Structural analysis revealed a key amino acid difference in TR LBDs, exploitable for beta-selectivity.
    • GC-1 demonstrated TRbeta-selective binding and cellular activity, with its structure suggesting specific hydrogen bonding interactions.
    • In vivo, GC-1 effectively lowered cholesterol and triglycerides without increasing heart rate or significantly affecting cardiac parameters, showing preferential distribution to the liver over the heart.

    Conclusions:

    • Compounds can be designed for selective thyroid hormone receptor modulation.
    • GC-1 represents a promising TRbeta-selective modulator with potential clinical utility for metabolic disorders.
    • Selective uptake and receptor targeting are key strategies for developing safer and more effective TR modulators.